Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Director/PDMR Share Purchases

6 Feb 2023 07:00

RNS Number : 9340O
Cambridge Cognition Holdings PLC
06 February 2023
 

6 February 2023

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Director/PDMR Share Purchases

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 3 February 2023 of the following purchases of the Company's ordinary shares by Directors and PDMRs of the Company.

The purchases made on 3 February 2023 are detailed in the table below:

Director/PDMR

No. of Ordinary Shares purchased

Purchase price per Ordinary Share

Total no. of Ordinary Shares held

Percentage ownership of total issued share capital

Matthew Stork

13,500

£1.11

161,450

0.47%

Stephen Symonds

10,000

£1.11

32,950

0.10%

Steven Powell

10,000

£1.11

226,375

0.65%

Richard Bungay

10,000

£1.11

10,000

0.03%

Debra Leeves

10,000

£1.12

60,000

0.16%

 

Further information on the purchases is contained in the disclosure tables below.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

For further information, please contact:

Cambridge Cognition Holdings Plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

 

Tel: 012 2381 0700 

press@camcog.com 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl

Rupert Dearden 

 

Tel: 020 7886 2500 

(Corporate Finance) 

(Corporate Broking) 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

 

Tel: 020 3903 7715 

 

IFC Advisory Ltd (Financial PR and IR) 

Tim Metcalfe / Graham Herring / Zach Cohen 

Tel: 020 3934 6630 

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Matthew Stork

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

£1.11

13,500

 

d)

Aggregated information

- Aggregated volume

- Price

13,500

£1.11

e)

Date of the transaction

3 February 2023

f)

Place of the transaction

London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Stephen Symonds

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

£1.11

10,000

 

d)

Aggregated information

- Aggregated volume

- Price

10,000

£1.11

e)

Date of the transaction

3 February 2023

f)

Place of the transaction

London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Steven Powell

2

Reason for the notification

a)

Position/status

Chairman

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

£1.11

10,000

 

d)

Aggregated information

- Aggregated volume

- Price

10,000

£1.11

e)

Date of the transaction

3 February 2023

f)

Place of the transaction

London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Bungay

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

£1.11

10,000

 

d)

Aggregated information

- Aggregated volume

- Price

10,000

£1.11

e)

Date of the transaction

3 February 2023

f)

Place of the transaction

London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Debra Leeves

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

£1.12

10,000

 

d)

Aggregated information

- Aggregated volume

- Price

10,000

£1.12

e)

Date of the transaction

3 February 2023

f)

Place of the transaction

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPUGCPUPWGMW
Date   Source Headline
1st Jun 20267:00 amRNS-RCOG to present at Mello 2026
28th May 20261:15 pmRNSLaunch of brain health study with Oura
21st May 20262:50 pmRNSResult of AGM
24th Apr 20263:16 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSResults for the year ended 31 December 2025
7th Apr 20267:01 amRNSNotice of Results
7th Apr 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
1st Apr 20267:00 amRNSBlock Listing Return
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
16th Feb 20267:00 amRNSCommercialisation Agreement
9th Feb 20267:00 amRNSChange of Joint Broker
19th Jan 20267:00 amRNSTrading Update
5th Nov 20257:01 amRNSChange of Auditor
5th Nov 20257:00 amRNSBoard Updates
1st Oct 20257:00 amRNSBlock Listing Return
29th Sep 20257:00 amRNSExercise of Options and Total Voting Rights
26th Sep 20259:59 amRNSHolding(s) in Company
8th Sep 20257:00 amRNSHolding(s) in Company
5th Sep 20252:51 pmRNSHolding(s) in Company
5th Sep 202512:04 pmRNSHolding(s) in Company
2nd Sep 20255:21 pmRNSHolding(s) in Company
1st Sep 202510:58 amRNS-RInvestor Presentation via Investor Meet Company
28th Aug 202510:45 amRNS£1.12m Placing & Subscription, TVR & PDMR Dealings
28th Aug 20257:01 amRNSChanges to Board and Management
28th Aug 20257:00 amRNSInterim Results
19th Aug 202510:10 amRNS-RMonument Therapeutics Partnership with FNIH
12th Aug 20257:00 amRNSLaunch of Speaker Identification Solution
31st Jul 20257:00 amRNSTrading update for period ended 30 June 2025
27th Jun 202512:27 pmRNSResult of AGM
24th Jun 20257:00 amRNS-RMonument Therapeutics Success in Phase I Results
4th Jun 20257:00 amRNSNotice of AGM
6th May 20255:59 pmRNSHolding(s) in Company
1st May 20257:00 amRNSPreliminary Unaudited Results
24th Apr 20257:00 amRNSNotice of Results and Investor Presentation
10th Apr 20257:00 amRNSContract Win
7th Apr 202510:24 amRNSHolding(s) in Company
3rd Apr 20257:00 amRNSContract Win
1st Apr 20257:00 amRNSBlock Listing Return
6th Mar 20257:00 amRNS-RCANTAB® used for major global brain health study
18th Feb 20257:00 amRNS-RCambridge Cognition submits FDA Letter of Intent
7th Feb 20257:00 amRNSBoard Appointment
21st Jan 20257:00 amRNSLaunch of in-house rater training service
16th Jan 20257:00 amRNSExpanded partnership with Actinogen
27th Dec 20243:34 pmRNSDirector/PDMR Share Purchases
23rd Dec 20244:02 pmRNSDirector/PDMR Share Purchases
16th Dec 20249:20 amRNSDirector/PDMR Share Purchases
10th Dec 20247:00 amRNSTrading Update
18th Nov 20244:02 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSMonument Therapeutics secures £1m investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.